Boehringer Ingelheim reported Phase 3 topline results for survodutide, its dual-acting obesity drug that targets GLP-1 and glucagon. In the Synchronize-1 trial of 725 participants, the company said weight loss was significantly greater than placebo and that treatment appeared to help preserve muscle mass. Boehringer licensed survodutide from Zealand Pharma. Wall Street commentary in the reporting described the weight loss profile as comparable to Wegovy but below Zepbound, while analysts awaited more detail on side effects and additional data in a liver disease (MASH) study. The Phase 3 readout extends the competitive pressure in obesity pharmacotherapy where lean-mass preservation has become a differentiator alongside percent weight loss.